The Lancet Neurology publishes positive results of AFFiRiS’ Phase 1 trial with PD01A in Parkinson’s disease patients
Repeated immunisation with PD01A is safe and well-tolerated over an extended time period Active immunisation with PD01A resulted in a substantial aSyn-specific antibody response and memory effect This antibody response